Cannabidiol reduces cigarette consumption in tobacco smokers: Preliminary findings

Addictive Behaviors

Volumn 38, Issue 9, 2013, Pages 2433-2436

  Morgan, Celia J A ^a   Das, Ravi K ^a   Joye, Alyssa ^a   Curran, H Valerie ^a   Kamboj, Sunjeev K ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Addiction; Cannabidiol; Endocannabinoids; Nicotine; Smoking cessation

Indexed keywords

CANNABIDIOL;

ADULT; ANXIETY; ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG BIOAVAILABILITY; FEMALE; FOLLOW UP; HUMAN; IMPULSIVENESS; MALE; METERED DOSE INHALER; MOOD CHANGE; PILOT STUDY; RANDOMIZED CONTROLLED TRIAL; SMOKING; SMOKING CESSATION; TOBACCO DEPENDENCE; TREATMENT DURATION; WITHDRAWAL SYNDROME;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANIMALS; CANNABIDIOL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MICE; PILOT PROJECTS; PLACEBOS; RATS; SMOKING; SMOKING CESSATION; TOBACCO USE DISORDER; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84878345442     PISSN: 03064603     EISSN: 18736327     Source Type: Journal    
DOI: 10.1016/j.addbeh.2013.03.011     Document Type: Article

References (27)

1. Arnone M., Maruani J., Chaperon F., Thiebot M.H., Poncelet M., Soubrie P., et al. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacology 1997, Jul, 132(1):104-106.
2. Beck A.T., Ward C.H., Mendelson M., Mock J., Erbaugh J. An inventory for measuring depression. Archives of General Psychiatry 1961, 4:561-571.
3. Bergamaschi M.M., Queiroz R.H., Zuardi A.W., Crippa J.A. Safety and side effects of cannabidiol, a Cannabis sativa constituent. Current Drug Safety 2011, Sep 1, 6(4):237-249.
4. Bond A.J., Lader M.H. The use of analogue scales in rating subjective feelings. The British Journal of Medical Psychology 1974, 47:7.
5. Bowen S., Marlatt A. Surfing the urge: Brief mindfulness-based intervention for college student smokers. Psychology of Addictive Behaviors 2009, 23(4):666-671.
6. Cahill K., Ussher M. Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database of Systematic Reviews 2007, 3:CD005353.
7. Cohen C., Perrault G., Griebel G., Soubrie P. Nicotine-associated cues maintain nicotine-seeking behavior in rats several weeks after nicotine withdrawal: Reversal by the cannabinoid (CB1) receptor antagonist, rimonabant (SR141716). Neuropsychopharmacology 2005, Jan, 30(1):145-155.
8. Cohen C., Perrault G., Voltz C., Steinberg R., Soubrie P. SR141716, a central cannabinoid (CB(1)) receptor antagonist, blocks the motivational and dopamine-releasing effects of nicotine in rats. Behavioural Pharmacology 2002, Sep, 13(5-6):451-463.
9. Cossu G., Ledent C., Fattore L., Imperato A., Bohme G.A., Parmentier M., et al. Cannabinoid CB1 receptor knockout mice fail to self-administer morphine but not other drugs of abuse. Behavioural Brain Research 2001, Jan 8, 118(1):61-65.
10. Crippa J.A., Derenusson G.N., Ferrari T.B., Wichert-Ana L., Duran F.L., Martin-Santos R., et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: A preliminary report. Journal of Psychopharmacology 2011, Jan, 25(1):121-130.
11. Etter J.F., Laszlo E., Zellweger J.P., Perrot C., Perneger T.V. Nicotine replacement to reduce cigarette consumption in smokers who are unwilling to quit: A randomized trial. Journal of Clinical Psychopharmacology 2002, Oct, 22(5):487-495.
12. Gest S. Behavioural inhibition: Stability and associations with adaptation from childhood to early adulthood. Journal of Personality and Social Psychology 1997, 72:8.
13. Gonzalez S., Cascio M.G., Fernandez-Ruiz J., Fezza F., Di Marzo V., Ramos J.A. Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Research 2002, Nov 1, 954(1):73-81.
14. Hughes J.R., Higgins S.T., Bickel W.K. Nicotine withdrawal versus other drug withdrawal syndromes: Similarities and dissimilarities. Addiction 1994, Nov, 89(11):1461-1470.
15. Le Foll B., Goldberg S.R. Rimonabant, a CB1 antagonist, blocks nicotine-conditioned place preferences. Neuroreport 2004, Sep 15, 15(13):2139-2143.
16. Leweke F.M., Piomelli D., Pahlisch F., Muhl D., Gerth C.W., Hoyer C., et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Translational Psychiatry 2012, Feb 21, 2:e94.
17. Morgan C.J., Freeman T.P., Schafer G.L., Curran H.V. Cannabidiol attenuates the appetitive effects of delta 9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology 2010, Aug, 35(9):1879-1885.
18. Navarro M., Carrera M.R., Fratta W., Valverde O., Cossu G., Fattore L., et al. Functional interaction between opioid and cannabinoid receptors in drug self-administration. The Journal of Neuroscience 2001, Jul 15, 21(14):5344-5350.
19. Parker L.A., Burton P., Sorge R.E., Yakiwchuk C., Mechoulam R. Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats. Psychopharmacology 2004, Sep, 175(3):360-366.
20. Ren Y., Whittard J., Higuera-Matas A., Morris C.V., Hurd Y.L. Cannabidiol, a nonpsychotropic component of cannabis, inhibits cue-induced heroin seeking and normalizes discrete mesolimbic neuronal disturbances. The Journal of Neuroscience 2009, Nov 25, 29(47):14764-14769.
21. Rodriguez De Fonseca F., Gorriti M.A., Bilbao A., Escuredo L., Garcia-Segura L.M., Piomelli D., et al. Role of the endogenous cannabinoid system as a modulator of dopamine transmission: Implications for Parkinson's disease and schizophrenia. Neurotoxicity Research 2001, Jan, 3(1):23-35.
22. Scherma M., Panlilio L.V., Fadda P., Fattore L., Gamaleddin I., Le Foll B., et al. Inhibition of anandamide hydrolysis by cyclohexyl carbamic acid 3'-carbamoyl-3-yl ester (URB597) reverses abuse-related behavioral and neurochemical effects of nicotine in rats. The Journal of Pharmacology and Experimental Therapeutics 2008, Nov, 327(2):482-490.
23. Serrano A., Parsons L.H. Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors. Pharmacology & Therapeutics 2011, Dec, 132(3):215-241.
24. Spielberger C.D., Gorusch R.L., R.D.L. STAI manual 1970, Consulting Psychologist Press, Palo Alto.
25. Stern C.A., Gazarini L., Takahashi R.N., Guimarães F.S., Bertoglio L.J. On disruption of fear memory by reconsolidation blockade: evidence from cannabidiol treatment. Neuropsychopharmacology. 2012, 2012(37):2132-2142.
26. Taylor J.R., Olausson P., Quinn J.J., Torregrossa M.M. Targeting extinction and reconsolidation mechanisms to combat the impact of drug cues on addiction. Neuropharmacology 2009, 56:186-195.
27. Vinklerova J., Novakova J., Sulcova A. Inhibition of methamphetamine self-administration in rats by cannabinoid receptor antagonist AM 251. Journal of Psychopharmacology 2002, Jun, 16(2):139-143.